JAK Inhibitor Safety Concerns vs Rebates: Which Will Impact Atopic Dermatitis Drug Access More?

 
• By Cathy Kelly

ICER discussion on the health benefit of several upcoming drugs for atopic dermatitis, including several JAK inhibitors, touches on safety concerns and the likelihood that increased competition will open the door to higher list prices and rebating in the class.

Several New Competitors Headed To Atopic Dermatitis Class

More from Market Access

More from Pink Sheet